Sanofi: BarCap upgrades 'underweight' rating
(CercleFinance.com) - Barclays Capital (BarCap) has upgraded its recommendation on the Sanofi stock from "underweight" to "equal weight," having increased its target price for the share 80 euros, recognising that there is a turning point - both regarding investors' sentiment around the share and the group's operating performance.
The broker still believes that there are grounds for caution, it says; for example, noting that multiple sclerosis is under pressure and that hemophilia will also be affected, while it believes that Dupixent is facing a battle in asthma.
Nevertheless, BarCap believes that in the nearer term, the group's outlook is more balanced, amongst other things, highlighting a low valuation in absolute terms and evidence that diabetes has bottomed out relative to expectations.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The broker still believes that there are grounds for caution, it says; for example, noting that multiple sclerosis is under pressure and that hemophilia will also be affected, while it believes that Dupixent is facing a battle in asthma.
Nevertheless, BarCap believes that in the nearer term, the group's outlook is more balanced, amongst other things, highlighting a low valuation in absolute terms and evidence that diabetes has bottomed out relative to expectations.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.